Les Laboratoires Servier

Pharmacyclics, Inc.

Shanghai Institute of Pharmaceutical Industry

Les Laboratories Servier

Philippe Letellier

Michael Lynch

Marina Gaillard

Jean-Pierre Lecouve

Jean-Michel Lerestif

Hanbin Shan

Alexandre Le Flohic

Anne Pimont-Garro

Yuhui Shen

Ying Luo

Nicolas Robert

Jérôme Guidotti

Loic Meunier

Mathieu Boiret

Jean-Manuel Pean

David Lafargue

Cécile Poirier

Cecile Poirier

Jerome Guidotti

Loïc Meunier

Described herein are salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, in particular that of formula (I): wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or hydrates thereof, and crystalline forms thereof characterized by the powder X-ray diffraction diagram and the 13C CP/MAS NMR solid state spectrum. Also described are compositions, methods of use and preparation thereof.

Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II):  Medicinal products containing the same which are useful in treating cancer.

Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it

Abexinostat tosylate of formula (II): and its crystalline form I characterized by its X-ray powder diffraction diagram, its Raman spectrum and its solid-stateC CP/MAS NMR spectrum. Medicinal products containing the same which are useful in the treatment of cancer.

Salt or abexinostat, associated crystalline form, a process for their preparation and pharmaceutical compositions containing them

3-[3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II):  Medicinal products containing the same which are useful in treating cancer.

Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing I

The present invention relates to new forms of co-crystals of agomelatine and p-toluenesulphonic acid, to a process for their preparation and to pharmaceutical compositions containing them. The co-crystals according to the invention have better solubility than agomelatine and are therefore more suitable for the preparation of pharmaceutical compositions. They also have better stability and purity and, moreover, are obtained by a simple process which does not include any difficult steps. 

Forms of co-crystals of agomelatine and p toluenesulphonic acid, a process for their preparation and pharmaceutical compositions containing them

Complexes of agomelatine and sulphonic acids of formula (I):  Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.

Complexes of agomelatine and sulphonic acids, a process for their preparation and pharmaceutical compositions containing them

Abexinostat tosylate of formula (II): and its crystalline form I characterized by its X-Ray powder diffraction diagram, its Raman spectrum and its solid-stateC CP/MAS NMR spectrum. Medicinal products containing the same which are useful in the treatment of cancer.

Salt of abexinostat, associated crystalline form, a process for their preparation and pharmaceutical compositions containing them

Industrial synthesis process for the compound of formula (I): 

[object Object]

New co-crystal of agomelatine composed of:  Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.

Co-crystals of agomelatine, a process for there preparation and pharmaceutical compositions containing them

Industrial synthesis process for, and crystalline form I of, the compound of formula (I): and also crystalline form I of the associated free base. Medicinal products containing the same which are useful in the treatment of disorders of the histaminergic system.

Growing community of inventors

Orleans, France

Philippe Letellier